Vanguard Personalized Indexing Management LLC Raises Holdings in Koninklijke Philips N.V. $PHG

Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Koninklijke Philips N.V. (NYSE:PHG) by 15.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,610 shares of the technology company’s stock after purchasing an additional 6,978 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Koninklijke Philips were worth $1,264,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Bessemer Group Inc. increased its stake in shares of Koninklijke Philips by 2,935.4% during the 1st quarter. Bessemer Group Inc. now owns 1,973 shares of the technology company’s stock worth $51,000 after purchasing an additional 1,908 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of Koninklijke Philips by 1,170.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,439 shares of the technology company’s stock worth $62,000 after purchasing an additional 2,247 shares in the last quarter. Blue Trust Inc. increased its stake in shares of Koninklijke Philips by 30.0% during the 2nd quarter. Blue Trust Inc. now owns 4,408 shares of the technology company’s stock worth $106,000 after purchasing an additional 1,017 shares in the last quarter. Allworth Financial LP increased its stake in shares of Koninklijke Philips by 16.2% during the 1st quarter. Allworth Financial LP now owns 4,638 shares of the technology company’s stock worth $115,000 after purchasing an additional 645 shares in the last quarter. Finally, Wealthquest Corp purchased a new position in shares of Koninklijke Philips during the 1st quarter worth approximately $116,000. 13.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PHG. Wall Street Zen lowered shares of Koninklijke Philips from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Weiss Ratings restated a “sell (d+)” rating on shares of Koninklijke Philips in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

Koninklijke Philips Stock Up 0.7%

Shares of NYSE PHG opened at $28.54 on Friday. Koninklijke Philips N.V. has a 1 year low of $21.48 and a 1 year high of $32.25. The firm’s 50 day moving average price is $27.69 and its 200 day moving average price is $25.35. The firm has a market cap of $27.48 billion, a P/E ratio of 150.18, a price-to-earnings-growth ratio of 0.77 and a beta of 0.82. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.81 and a current ratio of 1.26.

Koninklijke Philips (NYSE:PHG) last announced its quarterly earnings results on Tuesday, July 29th. The technology company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.12. The company had revenue of $5.05 billion for the quarter, compared to analyst estimates of $4.35 billion. Koninklijke Philips had a net margin of 1.00% and a return on equity of 11.95%. As a group, sell-side analysts anticipate that Koninklijke Philips N.V. will post 1.63 earnings per share for the current year.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.